

Occurrence of Pneumothorax and Pneumomediastinum in Covid-19 patients during non-invasive ventilation with Continuous Positive Airway Pressure

Author: Gidaro Antonio¹, Samartin Federica¹, Brambilla Anna M.¹, Cogliati Chiara¹, Ingrassia Stella¹, Banfi Francesco¹, Cupiraggi Viola¹, Bonino Cecilia¹, Schiuma Marco¹, Giacomelli Andrea¹, Rusconi Stefano¹, Salvi Emanuele¹

¹ Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital, Milan, Italy

Corresponding Author: Gidaro Antonio

Antonio Gidaro, MD,

Tel+39 3401595182

Mail: gidaro.antonio@asst-fbf-sacco.it

Address : Via G. B. Grassi N° 74 H. Sacco Milan 20157

The Authors declare no conflicts of interest, no financial support.

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

ABSTRACT Background: Acute Hypoxemic Respiratory Failure (AHRF) is a common complication of Covid-19 related pneumonia, for which non-invasive ventilation (NIV) with Helmet Continuous Positive Airway Pressure (CPAP) is widely used. During past epidemics of SARS and MERS pneumomediastinum (PNM) and pneumothorax (PNX) were common complications (respectively 1.7-12% and 16,4%) either spontaneous or associated to ventilation.

Methods: Aim of our retrospective study was to investigate the incidence of PNX/PNM in COVID-19 pneumonia patients treated with CPAP. Moreover, we examined the correlation between PNX/PNM and Positive end-expiratory pressure (PEEP) values. We collected data from patients admitted to “Luigi Sacco” University Hospital of Milan from 21/02/2020 to 06/05/2020 with COVID-19 pneumonia requiring CPAP. **Results:** One-hundred-fifty-four patients were enrolled. During hospitalization 3 PNX and 2 PNM occurred (3.2%). Out of these five patients 2 needed invasive ventilation after PNX, two died. In the overall population, 42 patients (27%) were treated with High-PEEP (>10 cmH₂O), and 112 with Low-PEEP (≤ 10 cmH₂O). All the PNX/PNM occurred in the High-PEEP group (5/37 vs 0/112, $p < 0,001$). **Conclusion:** The incidence of PNX appears to be lower in COVID-19 than SARS and MERS, but their occurrence is accompanied by high mortality and worsening of clinical conditions. Considering the association of PNX/PNM with high PEEP we suggest using the lower PEEP as possible to prevent these complications.

KEYWORDS: Pneumothorax, Pneumomediastinum, CPAP, PEEP, COVID-19

“Key messages” box

Section 1: What is already known on this subject

- Elevated incidence of pneumomediastinum (PNM) and pneumothorax (PNX) occurring during SARS and MERS pneumonia (respectively 1.7-12%^{9,10} and 16,4%¹¹), either spontaneous or associated to ventilation. Conversely, these complications have not been reported when NIV was used for the treatment of common pneumonia patients^{6,7}.
- Some cases of PNX and PNM have been recently reported in patients with COVID-19 pneumonia, most of them spontaneous¹²⁻¹⁴, in some cases related to NIV^{15,16} or endotracheal intubation (ETI)^{17,18}.

Section 2: What this study adds

- Incidence of PNX/PNM is lower in COVID19 pneumonia patients during CPAP (3,2%) than SARS and MERS.
- Considering mortality rate and need of ETI, occurrence of PNX/PNM worsens prognosis.
- All the PNX/PNM occurred in the High-PEEP (>10 cmH₂O) group (5/37 vs 0/112, p<0,001).
- Considering the association of high PEEP (>10 cmH₂O) with PNX/PNM, the use of low PEEP values has to be taken into consideration.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes severe disease (with dyspnoea, hypoxia, or >50 percent lung involvement on imaging within 24 to 48 hours) in 14% of patients, even leading to critical disease – Acute Hypoxemic Respiratory Failure (AHRF) or Acute Respiratory Distress Syndrome (ARDS) – in 5%¹.

During this novel coronavirus pandemic, non-invasive ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) was widely used to treat AHRF gaining respiratory support². NIV was already been used during SARS and MERS epidemic with some evidence of efficacy³⁻⁵ and some works support its use in pneumonia^{6,7}. Moreover, during COVID-19 outbreak the overcrowding of the ICUs pushed to use a bridge or alternative respiratory support in medical wards. During SARS epidemic in 2002 NIV was used to treat acute respiratory failure in SARS pneumoniae with different device: Helmet CPAP, Nasal CPAP, BiPaP^{3,4}. Between many interfaces available for CPAP therapy, the helmet has been proposed to reduce droplet dispersion and consequently preventing health care worker's infection⁸ during COVID-19 pandemic. For the same reason, the antimicrobial filter was adopted. In the past epidemics 4 to 15 cmH₂O^{3,4} of positive end-expiratory pressure (PEEP) have been administered, being higher PEEP contraindicated because of the elevated incidence of pneumomediastinum (PNM) and pneumothorax (PNX) occurring during SARS and MERS pneumonia (respectively 1.7-12%^{9,10} and 16,4%¹¹), either spontaneous or associated to ventilation. Conversely, these complications have not been reported when NIV was used for the treatment of common pneumonia patients^{6,7}.

Some cases of PNX and PNM have been recently reported in patients with COVID-19 pneumonia, most of them spontaneous¹²⁻¹⁴, in some cases related to NIV^{15,16} or endotracheal intubation (ETI)^{17,18}.

The first aim of our study was to assess the incidence of PNx and PNM in COVID-19 pneumonia patients treated with Helmet CPAP. Moreover, we investigated the correlation between the incidence of PNx or PNM and the PEEP values used during treatment.

MATERIALS AND METHODS

Study design and setting

We retrospectively analysed data from patients admitted in Hospital Wards of “Luigi Sacco” University Hospital of Milan from the Emergency Department (ER) or transferred from other hospitals of Lombardy region from 21/02/2020 to 06/05/2020.

The inclusion criteria were: 1) Chest X-Ray positive for pneumonia SARS-CoV-2 related. SARS-CoV-2 infection was defined by the positivity of real-time reverse transcription-polymerase chain reaction test (rt-PCR) at nose-pharyngeal swab with pneumonia 2) acute hypoxemic respiratory failure requiring helmet CPAP treatment, according to clinical judgement.

The exclusion criterion was the need of endotracheal intubation (ETI) for any reason except those who needed ETI after PNx/PNM.

We divided the index population in two groups according to PEEP level used under CPAP (≤ 10 cmH₂O and >10 cmH₂O).

PNx and PNM were documented with chest X-ray, usually carried out for worsening of clinical conditions .

The study (“REGISTRO DELLE INFEZIONI SOSPETTE E ACCERTATE COVID-19/Studio Sacco COVID-19”) was approved by the local ethical committee with the registration number 2020/16088.

Statistical Analysis

Kolmogorov-Smirnov test was done to evaluate the normality of distribution of data. Qualitative data were expressed as number and percentage. Chi square or Fisher exact tests were used in group’s comparison. Quantitative data were expressed as mean, standard deviation, median and

range. Student T-test and Mann-Whitney test (for non-parametric data) were used for comparison between groups. *P*-value less than 0.05 was considered statistically significant.

The statistical analysis of data was done by using *Excel* (Office program 2010) and *SPSS* (statistical package for social science-SPSS, Inc., Chicago, IL version 20).

RESULTS

During the observational period 1016 patients were admitted to our Hospital, 194 (19,1%) met the inclusion criteria. Of them, 40 patients (20,62%) were excluded because they needed ETI. In the end 154 (15.2%) patients were enrolled.

In Table 1 are summarized clinical characteristics of the examined population; the average age was 68.8 years (\pm 14.7), 107 were men (69.5%). CPAP was performed with PEEP set up between 5 to 15 cmH₂O (modal value 10 cmH₂O) and FiO₂ from 30% to 100%. The average duration of CPAP treatment was 174 hours – 6,4 days – with a great inhomogeneity (\pm 141). Mortality rate for the whole population was 25.3%.

During the observational period 5 events occurred, of which 3 were PN_X and 2 PN_M. Between cases, 3 were male patients, no one had a passed story of smoking or underlying lung disease, nobody has undergone invasive manoeuvres (as positioning central venous catheter or thoracentesis). The most relevant features of these five patients are reported in Table 2.

After the event, every patient needed higher FiO₂ (from 50-60% to 100%); 2 underwent chest drainage and subsequently ETI (Figure 1) and then died with a mortality rate of 40%. The average time elapsed from starting CPAP to the occurrence of PN_X/PN_M was 180 hours with great inhomogeneity (\pm 137).

No difference was found in the duration of CPAP treatment between PN_X/PN_M group and No-PN_X/PN_M patients (p-value 0.931).

High-PEEP (>10 cmH₂O) was administered to 42 (27,3%) patients, and Low-PEEP (\leq 10 cmH₂O) to 112 (72.7%). As shown in Table 1, no statistical differences in term of characteristics were found

comparing High-PEEP vs Low-PEEP group. The PNX/PNM occurred only in the High-PEEP group (5/42, 12% vs 0/112, 0%, $p < 0.001$).

DISCUSSION

In our retrospective observational study PNX/PMN occurred in 3.2% of patients; apparently, nobody had previous risk factors for PNX (no smokers, no lung diseases, no positioning central venous catheter or thoracentesis). Among these cases, the incidence of negative outcome (mortality and ETI) is relevant. Moreover, even in survived patients, events were associated with worsening of clinical conditions with a higher need of FiO₂ (50-60% before vs 100% after).

PNX and PNM occurred only in the High-PEEP group (11.9%). Considering the homogeneity of these groups in terms of clinical and biochemical features, we may suppose that elevated PEEP may represent a risk factor for PNX/PNM in COVID-19 patients. Conversely, in our population duration of CPAP treatment was quite variable and does not seem to play a determinant role as risk factor for events.

The possible effect of barotrauma has to be considered as superimposed to the direct effect of lung damage related to Covid-19 pneumonia. PNX and PNM occurred rather frequently in SARS and MERS patients. Some study addressing evolution of lung lesions on CT imaging showed that in many cases spontaneous PNM occurred when ground glass opacity and consolidations began to resolve^{11,19}. The pathogenesis of this phenomenon has been interpreted as the effect of the peribronchiolar inflammatory nodule formation, leading to interstitial pulmonary emphysema, tracking back along the broncho-vascular sheath and reaching the mediastinum¹⁹. On the other hand, histologic findings (alveolar damage with pulmonary oedema and hyaline membrane formation) appear to support the hypothesis that severe pulmonary injury predisposes the patient to spontaneous pneumothorax²⁰. The diffuse alveolar damage may give rise to dilated cystic air spaces and honeycombing predisposing the lung to air leakage from the rupture of the cystic lesions, with the consequent development of a pneumothorax. Possible shared mechanisms may underly

PNX/PNM in patients with COVID-19 pneumonia considering the presence of similar lung damages and imaging features as described for SARS^{21,22}.

In our study PNX/PNM happened after a long time from onset of symptoms (18 days in average) resembling what previously described in SARS patients¹⁰ and suggesting that a sustained period of lung inflammation might be required. Conversely, we did not find significant differences in the biochemical elements of disease severity (peak LDH and neutrophil count) that seemed to be predictable of spontaneous pneumothorax in SARS patients¹⁰.

Finally, in the past SARS epidemic someone conjectured that steroid therapy may play a role in the pathogenesis of spontaneous pneumothorax because it could delay wound healing and perpetuate air leakage¹⁰. In our study only 2 out of 5 patients have been treated with steroid therapy, so we can not speculate about this hypothesis.

Our study has several limitations. First of all, the number of events is low and for this reason our results, and in particular the association of PNX/PNM with higher PEEP, has to be confirmed in multicentric studies with a wider population. Moreover, our study is retrospective: PEEP values were decided by the clinician for each patient and in particular higher PEEP values have been set in the first weeks and subsequently lowered on the basis of clinical experience and data emerging from literature. In the end, we did not collect data about pneumoperitoneum or subcutaneous emphysema which can be classified as possible barotrauma even if rare.

CONCLUSION

In conclusion, our study indicates that incidence of PNX/PNM is lower in COVID-19 pneumonia patients than SARS and MERS⁹. Nevertheless, the occurrence of these events significantly worsens the prognosis. Considering the association of high PEEP (>10 cmH₂O) with PNX/PNM, the use of low PEEP values has to be taken into consideration.

BIBLIOGRAPHY

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. February 2020. doi:10.1001/jama.2020.2648
2. Radovanovic D, Rizzi M, Pini S, Saad M, Chiumello DA, Santus P. Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal. *J Clin Med*. 2020;9(4):1191. doi:10.3390/jcm9041191
3. YAM LY, CHEN RC, ZHONG NS. SARS: ventilatory and intensive care. *Respirology*. 2003;8(s1):S31-S35. doi:10.1046/j.1440-1843.2003.00521.x
4. Zhao Z. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J Med Microbiol*. 2003;52(8):715-720. doi:10.1099/jmm.0.05320-0
5. Alraddadi BM, Qushmaq I, Al-Hameed FM, et al. Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. *Influenza Other Respi Viruses*. 2019;13(4):382-390. doi:10.1111/irv.12635
6. Brambilla AM, Prina E, Ferrari G, et al. Non-invasive positive pressure ventilation in pneumonia outside Intensive Care Unit: An Italian multicenter observational study. *Eur J Intern Med*. 2019;59(August 2018):21-26. doi:10.1016/j.ejim.2018.09.025
7. Brambilla AM, Aliberti S, Prina E, et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia [published correction appears in Intensive Care Med. 2014 Aug;40(8):1187]. *Intensive Care Med*. 2014;40(7):942-949. doi:10.1007/s00134-014-3325-5
8. Cabrini L, Landoni G, Zangrillo A. Minimise nosocomial spread of 2019-nCoV when treating acute respiratory failure. *Lancet*. 2020;395(10225):685. doi:10.1016/S0140-

6736(20)30359-7

9. Peiris J, Chu C, Cheng V, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet*. 2003;361(9371):1767-1772. doi:10.1016/S0140-6736(03)13412-5
10. Sihoe ADL, Wong RHL, Lee ATH, et al. Severe Acute Respiratory Syndrome Complicated by Spontaneous Pneumothorax. *Chest*. 2004;125(6):2345-2351. doi:10.1378/chest.125.6.2345
11. Das KM, Lee EY, Jawder SE Al, et al. Acute Middle East Respiratory Syndrome Coronavirus: Temporal Lung Changes Observed on the Chest Radiographs of 55 Patients. *Am J Roentgenol*. 2015;205(3):W267-S274. doi:10.2214/AJR.15.14445
12. Rohailla S, Ahmed N, Gough K. SARS-CoV-2 infection associated with spontaneous pneumothorax. *Can Med Assoc J*. 2020;192(19):E510-E510. doi:10.1503/cmaj.200609
13. Flower L, Carter J-PL, Rosales Lopez J, Henry AM. Tension pneumothorax in a patient with COVID-19. *BMJ Case Rep*. 2020;13(5):e235861. doi:10.1136/bcr-2020-235861
14. Mohan V, Tauseen RA. Spontaneous pneumomediastinum in COVID-19. *BMJ Case Rep*. 2020;1-2. doi:10.1136/bcr-2020-236519
15. Al-shokri SD, Ahmed AOE, Saleh AO, Aboukamar M, Ahmed K, Mohamed MFH. Case Report □: COVID-19 – Related Pneumothorax — Case Series Highlighting a Significant Complication. 2020;(Table 1):2-5. doi:10.4269/ajtmh.20-0713
16. Sun R, Liu H, Wang X. Mediastinal Emphysema , Giant Bulla , and Pneumothorax Developed during the Course of COVID-19 Pneumonia. *Korean J Radiol*. 2020;21(5):541-544. doi:10.3348/kjr.2020.0180
17. Yao W, Wang T, Jiang B, et al. Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international expert recommendations. *Br J Anaesth*. 2020;125(April):28-37. doi:10.1016/j.bja.2020.03.026
18. Volpi S, Ali JM. Pneumomediastinum in COVID-19 patients □: a case series of a rare

- complication. *Eur J Cardio-Thoracic Surg*. 2020;0:1-2. doi:10.1093/ejcts/ezaa222
19. Müller NL, Ooi GC, Khong PL, Zhou LJ, Tsang KWT, Nicolaou S. High-Resolution CT Findings of Severe Acute Respiratory Syndrome at Presentation and after Admission. *Am J Roentgenol*. 2004;182(1):39-44. doi:10.2214/ajr.182.1.1820039
 20. Franks TJ, Chong PEKY, Chui P, et al. Lung Pathology of Severe Acute Respiratory Syndrome (SARS): A Study of 8 Autopsy Cases From Singapore. *Hum Pathol*. 2003;(August). doi:10.1016/S0046-8177(03)00367-8
 21. Lei P, Mao J, Wang P. Spontaneous Pneumomediastinum in a Patient with Coronavirus Disease 2019 Pneumonia and the Possible Underlying Mechanism. *Korean J Radiol*. 2020;21(7):929. doi:10.3348/kjr.2020.0426
 22. Carsana L, Sonzogni A, Nasr A, et al. Articles Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy□: a two-centre descriptive study. *Lancet Infect Dis*. 2020;3099(20):6-11. doi:10.1016/S1473-3099(20)30434-5

	GENERAL POPULATION	LOW PEEP GROUP	HIGH PEEP GROUP	P VALUE
Number of patients	154	112	42	
Age (years)	65.8 ± 14.7	65.8 ± 14.5	66.0 ± 15.4	0.9
Male Sex	107 (69.5%)	73 (65.2%)	34 (80.9%)	0.058
PNX/PNM	5 (3.2%)	0 (0%)	5 (11.9%)	<0.001
Deaths	39 (25.3%)	24 (21.4%)	15 (35.7%)	0.069
Tocilizumab	50 (32.5%)	33 (29.5%)	17 (40.5%)	0.183
High dose steroids	16 (10.4%)	12 (10.7%)	4 (9.5%)	0.829
Delirium	39 (25.3%)	24 (21.4%)	15 (35.7%)	0.069
Antiviral therapy	100 (64.9%)	71 (63.4%)	29 (69.1%)	0.512
RR at T0 (bpm)*	27 ± 7	26 ± 7	27 ± 8	0.63
pO2 at T0 (mmHg) ¥	68.3 ± 21.8	67.9 ± 22.0	69.2 ± 21.6	0.74
pCO2 at T0 (mmHg) □	33.1 ± 7.2	33.2 ± 7.9	32.9 ± 5.3	0.81
pH at T0	7.47 ± 0.06	7.47 ± 0.06	7.46 ± 0.07	0.32
Bicarbonates at T0 (mmol/L)	24.0 ± 4.1	24.2 ± 4.3	23.5 ± 3.6	0.36
FiO2 at T0 (%)	40.3 ± 25.3	37.7 ± 23.9	47.1 ± 27.83	0.058
pO2/FiO2 at T0	223 ± 100	232 ± 96	202 ± 108	0.1
Lactate at T0 (mmol/L)	1.65 ± 1.31	1.57 ± 0.98	1.91 ± 1.95	0.15
SO2 at T0 (%) △	92.6 ± 7.0	92.6 ± 7.0	92.5 ± 7.0	0.95
Length of hospitalization (days)	20.3 ± 14.4	20.8 ± 15.0	19.1 ± 13.0	0.52
Duration of CPAP (hours)	174.5 ± 140.8	177.3 ± 150.0	166.8 ± 113.7	0.68
Duration of symptoms (days)	7.3 ± 3.9	7.1 ± 3.9	7.6 ± 3.9	0.49
CCI ~	2.91 ± 2.34	2.98 ± 2.35	2.74 ± 2.35	0.60
CRP (mg/L) ⊙	159 ± 92	158 ± 93	161 ± 92	0.85
IL-6	144 ± 412	103 ± 211	246 ± 687	0.248
Granulocytes (/μL)	7022 ± 8814	7270 ± 10186	6361 ± 2933	0.58

Lymphocytes (μL)	1247 \pm 2279	1327 \pm 2603	1039 \pm 1015	0.49
GRs/Ly ratio \square	8.1 \pm 7.1	7.7 \pm 5.7	9.1 \pm 9.9	0.28

Table 1. Characteristic of examined population and the 2 groups according to PEEP value

Continuous variables are expressed as mean \pm standard deviation

T0 = before starting CPAP

* Respiratory rate before starting CPAP

¥ Partial pressure of oxygen in arterial blood

\square Partial pressure of carbon dioxide in arterial blood

Δ Oxygen saturation in arterial blood

~ Charlson Comorbidity Index

\ominus C-Reactive Protein

\square Granulocytes/Lymphocytes ratio

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5
AGE (YEARS)	42	78	46	78	70
SEX	Male	Female	Male	Male	Female
SMOKING HISTORY	No	No	No	No	No
CHARLSON INDEX	0	3	0	4	3
UNDERLYING LUNG DISEASE	No	No	No	No	No
CHEST RX FINDINGS ON HOSPITAL ADMISSION	Right upper lobe and bilateral lower	Left upper lobe and right lower lobe	Bilateral all lobe	Bilateral all lobe	Bilateral medium and low lobe
PEAK LDH (U/L)	313	662	671	507	634
PEAK PCR (MG/L)	203	209	142	260	372
PEAK IL6 (NG/L)	76	65	60	105	Not Performed
PEAK D-DIMER (MG/L FEU)	426	3443	795	5985	3213
LOWEST LYMPHOCYTE COUNT (10⁶/L)	860	640	1200	750	330
TIME FROM BEGINNING OF SYMPTOMS AND PNX (DAYS)	17	23	9	23	10
TIME BETWEEN STARTING CPAP AND PNX/PMN (HOURS)	168	170	72	408	72
PEEP CPAP (CMH₂O)	12,5	15	12,5	12,5	12,5
HIGHER FIO₂ DURING CPAP	60%	60%	60%	60%	50%
HIGHER FIO₂ AFTER PNX/PMN	100%	100%	100%	100%	100%
SIDE OF PNX	Bilateral	No	Left lung	No	Bilateral
PNM	No	Yes	No	Yes	Yes
ANTIVIRAL THERAPY	Ritonavir/Lopinavir	Ritonavir/Lopinavir + Remdesivir	Ritonavir/Lopinavir	Ritonavir/Lopinavir + Remdesivir	Ritonavir/Lopinavir + Remdesivir
USE OF STEROID	No	Yes	No	Yes	No
USE OF TOCILIZUMAB	Yes	Yes	No	No	No
REQUIRED ETI AFTER PNX	No	No	Yes	No	Yes
CHEST DRAINAGE AFTER PNX	No	No	Yes	No	Yes
TIME FROM PNX AND DISCHARGE/DEATH (DAYS)	18	20	5	54	25
DEATH	No	No	Yes	No	Yes

Table 2. Clinical and biochemical features about 5 cases of PNX/PMN

Figure 1: Example of PNX as visualized at Chest X-Ray (Case 3; left PNX, arrows) before (A) and after (B) drainage and ETI.

